WO2000029852A1 - A method of detecting the presence of an analyte in a biological sample - Google Patents
A method of detecting the presence of an analyte in a biological sample Download PDFInfo
- Publication number
- WO2000029852A1 WO2000029852A1 PCT/AU1999/001014 AU9901014W WO0029852A1 WO 2000029852 A1 WO2000029852 A1 WO 2000029852A1 AU 9901014 W AU9901014 W AU 9901014W WO 0029852 A1 WO0029852 A1 WO 0029852A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- region
- test matrix
- analyte
- biological sample
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/726—Devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/725—Haemoglobin using peroxidative activity
Definitions
- the present invention relates generally to a method of detecting the presence of an analyte in a biological sample. More particularly, the present invention provides a method of detecting the presence of blood in a biological sample and still more particularly, the presence of high concentrations of blood. The method of the present invention also facilitates the differentiation of upper and lower gastrointestinal tract bleeding. The method of the present invention is useful, inter alia, for the diagnosis of gastrointestinal tract diseases and, in particular, lower gastrointestinal tract diseases such as colorectal cancer.
- Bleeding into the bowel is currently the best early indicator of bowel cancer (also known as colorectal cancer). Testing for systems of bleeding into the bowel is usually achieved by screening stools for the presence of blood. This test is often referred to as faecal occult blood testing (referred to as "FOBT").
- FOBT faecal occult blood testing
- the inventor has developed a method of screening biological samples for the presence of blood utilising a two part testing procedure which comprises an immunological screen for the presence of the globin component of haemoglobin performed and a non-immunological screen for the haem component of haemoglobin. Accordingly, even if the immunological detection method utilised to screen for globin produces a false negative result due to the presence of high concentrations of globin, the haem test which is not sensitive to the effects of the prozone phenomenon will nevertheless produce a positive result.
- the inventors have also developed an immunological screening method which overcomes the effects of the prozone phenomenon.
- the present invention provides a method of detecting the presence of blood in a biological sample, said method comprising the steps of: (i) applying a biological sample to a first region of a test matrix which test matrix comprises multiple regions;
- the present invention more particularly provides a method of detecting the presence of blood in a gastrointestinal sample, said method comprising the steps of :
- the present invention provides a method of detecting the presence of blood in a gastrointestinal sample, said method comprising the steps of: (i) applying a gastrointestinal sample to a first region of a test matrix which test matrix comprises multiple regions;
- Another aspect of the present invention is directed to a method of detecting lower gastrointestinal bleeding, said method comprising the steps of:
- Yet another aspect of the present invention is directed to a method of detecting upper gastrointestinal tract bleeding, said method comprising the steps of:
- Yet another aspect of the present invention is directed to a method of diagnosing disease conditions, the symptoms of which include bleeding, said method comprising the steps of:
- the present invention is directed to a method of diagnosing colorectal cancer, said method comprising the steps of:
- the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
- test matrix (i) applying a biological sample to a first region of a test matrix, which test matrix comprising multiple regions;
- the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
- test matrix comprises multiple regions
- the present invention more particularly provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
- test matrix comprises multiple regions
- step (ii) wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).
- step (ii) in performing an analysis of the result obtained in step (ii) relative to the detection result in step (iii):
- step (b) a weaker positive detection result at step (ii) relative to a stronger positive detection of step (iii) is indicative of a low analyte concentration
- the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
- test matrix comprises multiple regions
- test matrix comprises multiple regions
- step (ii) wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).
- the present invention provides a method of detecting the presence of blood in a biological sample, said method comprising the steps of:
- test matrix comprises multiple regions
- step (iii) permitting flowing of uncomplexed conjugate to a third region of said test matrix wherein said uncomplexed conjugate is placed in contact with said haemoglobin, which haemoglobin is immobilised in said third region, for a time and under conditions sufficient for a haemoglobin-conjugate complex to form and detecting said complex; wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).
- the present invention is predicated, in part, on the development of a blood screening method which screens for both the globin component of haemoglobin and the haem component of haemoglobin.
- a blood screening method which screens for both the globin component of haemoglobin and the haem component of haemoglobin.
- the present invention provides a method of detecting the presence of blood in a biological sample, said method comprising the steps of:
- test matrix comprises first, second and third regions
- Chromogens suitable for use in the present invention include, but are not limited to, guaiac, tetramethyl benzidine, ortho tolidine or functional equivalents thereof.
- said chromogen is guaiac.
- the present invention more particularly provides a method of detecting the presence of blood in a biological sample, said method comprising the steps of:
- test matrix comprises first, second and third regions
- biological sample should be understood as a reference to any sample of biological material derived from an animal such, but not limited to, mucus, faeces, urine, biopsy specimens and fluid which has been introduced into the body of an animal and subsequently removed such as, for example, the saline solution extracted from the lung following lung lavage or the solution retrieved from an enema wash.
- the biological sample which is tested according to the method of the present invention may be tested directly or may require some form of treatment prior to testing. For example, a biopsy sample may require homogenisation prior to testing.
- the biological sample is not in liquid form, (for example it may be a solid, semi-solid or a dehydrated liquid sample) it may require the addition of a reagent, such as a buffer, to mobilise the sample.
- the mobilising reagent may be mixed with the biological sample prior to application of the sample to the test matrix or the reagent may be applied to the sample after the sample has been applied to the test matrix.
- the use of a mobilising reagent is required to facilitate flowing (wicking) of the sample along the test matrix.
- the biological sample is a gastrointestinal sample.
- gastrointestinal sample is meant any sample which is derived from the gastrointestinal tract. For example, faeces, mucus (for example the mucus from a rectal mucus swab), enema wash solution or a gastrointestinal tract biopsy sample.
- animal as used herein includes a human, primate, livestock animal (e.g. sheep, pig, cow, horse, donkey), laboratory test animal (e.g. mouse, rat, rabbit, guinea pig), companion animal (e.g. dog, cat), captive wild animal (e.g. fox, kangaroo, deer), aves (e.g. chicken, geese, duck, emu, ostrich), reptile or fish.
- livestock animal e.g. sheep, pig, cow, horse, donkey
- laboratory test animal e.g. mouse, rat, rabbit, guinea pig
- companion animal e.g. dog, cat
- captive wild animal e.g. fox, kangaroo, deer
- aves e.g. chicken, geese, duck, emu, ostrich
- reptile or fish e.g. chicken, geese, duck, emu, ostrich
- the present invention more particularly provides a method of detecting the presence of blood in a gastrointestinal sample said method comprising the steps of :
- test matrix comprises first, second and third regions
- said chromogen is guaiac or functional equivalent thereof.
- test matrix is a reference to any device which is suitable for sequentially testing a biological sample for the presence of the globin component of haemoglobin, utilising a immunological test, and the haem component of haemoglobin, using a chromogen or functional equivalent thereof.
- said test matrix is a chromatographic test strip which comprises a first region for receiving a biological sample and a second region which comprises two sections.
- the first section of the second region is an area of immobilised antiglobin antibody coupled to colloidal gold particles which are re- suspendible by a passing liquid front while the second section of the second region is an area of immobilised antiglobin capture antibody.
- the third region comprises an absorbent pad impregnated with guaiac.
- the third region may comprise a strip of guaiac impregnated paper which is laminated to the second region.
- the three regions detailed in the present invention may be positioned sequentially or in some other manner, such as superimposed.
- the first and second regions may be combined such that the sample is deliverable directly into the second region.
- the test matrix of the present invention may also comprise additional regions.
- the present invention envisages the use of chromatographic strips which comprises an absorbent pad located after the third region.
- the biological sample which is applied to the first region wicks from the first region to the second region and the detection of globin and haem is then performed as a sequential two step procedure.
- the globin component of any haemoglobin which is present in the sample is bound by the antiglobin antibody coupled to the colloidal gold particles.
- the passing biological sample front re-suspends these antibodies and both the globin-antiglobin complex and the free anti-globin antibody wick from the first section of the second region to the second section.
- the globlin component of any haemoglobin present in the sample becomes bound to the immobilised antiglobin capture antibody while free antiglobin coupled to colloidal gold, the non-glob in components of the biological sample and any excess globin which is not bound by the anti-globin antibodies of the second region continued to wick into the third region.
- the haem component of any haemoglobin which has not been captured at the second region reacts with a developer solution to cause the release of oxygen, which oxygen reacts with a chromogen such as guaiac to result in a colour change.
- a biological sample comprises high concentrations of blood, and therefore high concentrations of haemoglobin
- a false negative result may be obtained at the second region of the test matrix due to the prozone phenomenon.
- the third region of the test matrix which detects the haem component of haemoglobin based on the non-immunological chromogen reaction, will nevertheless produce a positive result. Accordingly, the incorporation of a non-immunological chromogen test with the immunological globin test provides a safe guard against obtaining false negative results due to the effects of the prozone phenomenon where high concentrations of blood are present in the sample.
- the method of the present invention requires that the haemoglobin of the red blood cells is exposed prior to commencement of the test. This may be achieved by any one of a number of methods known to those skilled in the art. For example, contacting the biological sample with a red blood cell lysis solution, prior to commencement of the test, would achieve this object. It is also within the scope of this invention to cleave the haem and the globin components of the haemoglobin either before the test begins or at some point before the biological sample wicks into the third region. In this way, it would be possible to minimize the incidence of the haem component being trapped by the antiglobin capture antibodies by virtue of its attachment to the globin component.
- immunointeractive molecule should be understood as a reference to any molecule comprising an antigen binding portion or a derivative of said molecule.
- molecules contemplated by this aspect of the present invention include, but are not limited to, monoclonal and polyclonal antibodies (including synthetic antibodies), hybrid antibodies, humanised antibodies, catalytic antibodies) and T cell antigen binding molecules.
- said immunointeractive molecule is an antibody.
- the present invention provides a method of detecting the presence of blood in a gastrointestinal sample said method comprising the steps of: (i) applying a gastrointestinal sample to a first region of a test matrix which test matrix comprises first, second and third regions;
- said biological sample is a faecal sample.
- said chromogen is guaiac or functional equivalent thereof.
- references to "functional equivalents” should be understood as a reference to fragments, parts, portions, mutants, homologues, mimetics from natural, synthetic or recombinant sources including fusion proteins which exhibit chromogen activity.
- Derivatives may be derived from insertion, deletion or substitution of amino acids.
- Amino acid insertional derivatives include amino and/or carboxylic terminal fusions as well as intrasequence insertions of single or multiple amino acids.
- Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product.
- Deletional variants are characterised by the removal of one or more amino acids from the sequence.
- Substitutional amino acid variants are those in which one residue in the sequence has been removed and a different residue inserted in its place. Additions to amino acid sequences include fusions with other peptides, polypeptides or proteins.
- a biological sample being "placed in contact" with an immunointeractive molecule or a chromogen should be understood as a reference to any method of facilitating the interaction of any one or more components of the biological sample with the immunointeractive molecule or the chromogen such that coupling, binding or other association between the one or more components of the biological sample and the immunointeractive molecule or a chemical reaction involving one or more components of the biological sample such that the chromogen colour change may occur (such as one or more components of the biological sample reacting with the developer to cause the release of oxygen which oxygen reacts with the chromogen to cause a colour change).
- the biological sample may be applied to a chromatographic strip which is impregnated with the immunointeractive molecule at the second region and the chromogen at the third region.
- the action of the biological sample wicking up the strip to the regions of impregnation place the sample in contact with the immunointeractive molecule or the chromogen.
- the biological sample may be applied to a chromatographic strip and the immunointeractive molecules or the chromogen may be added to the test strip at the time of testing such as simultaneously with the application of the biological sample or sequentially following the application of the biological sample.
- Detecting the formation of a globin-antiglobin complex or the chemical reaction between haem and the chromogen may be by any convenient method which will be known to those skilled in the art.
- the antiglobin antibody which becomes resuspended by the wicking biological sample front is complexed with colloidal gold.
- colloidal gold becomes visible as a pink band due to its increasing concentration during trapping of the complex at this point.
- the antiglobin antibody may be radio-labelled or enzymatically labelled such that upon addition of a substrate a colour change is observed if globin is present.
- the detection of haem by a chromogen is preferably achieved by the addition of a developer such as peroxide which reacts with haem to produce water and oxygen. The oxygen which is liberated then reacts with the chromogen to produce a colour change. For example, when guaiac reacts with oxygen a blue colour is produced.
- the chromogen may be incorporated into the test matrix at the third region together with the developer or else the developer may be added as a liquid reagent at a later stage.
- the paper will turn blue upon the arrival of aqueous haemoglobin.
- some other type of reporter molecule which detects the reactivity between the haem and the chromogen or functional equivalent thereof may be used.
- the present invention is used to diagnose gastrointestinal tract bleeding by analysing faecal samples for the presence of blood.
- the chromogen test will positively identify bleeding from any part of the gastrointestinal tract (that is, both the upper and lower regions of the tract) since it detects the haem component of haemoglobin and haem is relatively resistant to breakdown in the small intestine (the upper gastrointestinal tract).
- the globin component of haemoglobin however, does not survive passage through the upper gastrointestinal tract.
- a positive globin result in a faecal sample therefore indicates that bleeding has occurred in the lower gastrointestinal tract.
- Another aspect of the present invention is directed to a method of detecting lower gastrointestinal bleeding said method comprising the steps of:
- test matrix which test matrix comprises first, second and third regions;
- a positive haem result and a positive globin result is indicative of lower gastrointestinal tract bleeding.
- said chromogen is guaiac or functional equivalent thereof.
- Yet another aspect of the present invention is directed to a method of detecting upper gastrointestinal tract bleeding said method comprising the steps of:
- test matrix comprises first, second and third regions
- chromogen is guaiac or functional equivalent thereof.
- Yet another aspect of the present invention is directed to a method of diagnosing disease conditions, the symptoms of which include bleeding, said method comprising the steps of:
- test matrix comprises first, second and third regions
- the present invention is directed to a method of diagnosing colorectal cancer said method comprising the steps of:
- test matrix comprises first, second and third regions
- said chromogen is guaiac or functional equivalent thereof.
- the inventors have also surprisingly determined that by screening for the presence of unbound conjugate, in addition to screening for the analyte of interest, the effects of the prozone phenomenon can be overcome where an immunological screening technique is utilised.
- an immunological test screen is utilised to detect the presence of an analyte, which method relies on the capture of the subject analyte by both an immobilised immunointeractive molecule and a labelled immunointeractive molecule conjugate which ultimately provides the detection means, by analysing the level of unbound detection molecule relative to the analyte test result, the test results which often arise due to prozone effects, and which are often misleading, can be interpreted correctly.
- the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
- test matrix (i) applying a biological sample to a first region of a test matrix, which test matrix comprising multiple regions;
- an "anti-analyte immunointeractive conjugate” should be understood as reference to a molecule which can interact with the analyte of interest and which molecule either directly or indirectly facilitates the detection of the complexed, immobilised analyte described in step (ii), above.
- the conjugate interact in an antigen specific manner with the analyte of interest.
- Reference to "detecting” has the same meaning as hereinbefore defined.
- the conjugate will act "indirectly”, for example, if it requires an additional step to achieve visualisation of the analyte complex.
- the conjugate comprises an enzymatically labelled antibody, to which a substrate must be added in order to achieve a visually detectable colour change.
- the conjugate acts "directly” if no additional steps are required to achieve visualisation.
- the subject conjugate is an antibody coupled to colloidal gold, the colloidal gold will become visible as a pink band due to its increasing concentration during trapping of the conjugate.
- the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
- test matrix comprises multiple regions
- the conjugate may be detected in a non-specific manner such as via an immobilised anti-immunoglobin antibody which captures the subject conjugate.
- it may be detected in a specific manner such as via a region of immobilised antigen to which the antibody conjugate is specifically directed.
- the conjugate is detected in an antigen specific manner thereby facilitating the optional inclusion of a control test to confirm that wicking of the conjugate along the test matrix actually occurs.
- a typical control test may therefore take the form of a region of immobilised anti-immunoglobin antibody which captures a small portion of the immunoglobin conjugate.
- detection of the uncomplexed conjugate is achieved in an immunologically specific manner via a region of immobilised antigen to which the conjugate is specifically directed. This antigen is preferably the analyte of interest.
- the steps of immobilising the analyte of interest and detecting said analyte may be performed in any suitable manner.
- the steps may be performed sequentially or simultaneously.
- the biological sample is applied to an application region of a chromatographic strip, where it is placed in contact with a colloidal gold labelled anti-analyte antibody conjugate.
- the sample, together with any unbound conjugate is allowed to wick along the chromatographic strip to a second region where it contacts an immobilised anti-analyte antibody. Any analyte present in the sample will complex with the immobilised anti-analyte antibody.
- the analyte has previously complexed with the colloidal gold conjugate, it will become evident as a pink band which darkens as the labelled antibody is immobilised in the test region and its concentration increases. Any excess unbound conjugate together with the unbound biological sample components will continue to wick into a third region of the test matrix.
- the third region of the test matrix comprises immobilised analyte which will complex any unbound anti-analyte conjugate.
- the results also provide a general indication of the concentration of analyte present in the sample.
- the analyte of interest is haemoglobin
- a biological sample which does not contain any haemoglobin will produce a negative result in the second region and a strongly positive result in the third region where all the available conjugate will ultimately become complexed with the immobilised haemoglobin.
- analysis of the intensity of result obtained from step (ii) relative to the result obtained at step (iii) will be indicative of the concentration of analyte which is present in the biological sample in terms of whether the analyte is present in low, high or very high levels.
- the present invention more particularly provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
- test matrix comprises multiple regions
- step (ii) wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).
- step (ii) in performing an analysis of the result obtained in step (ii) relative to the detection result in step (iii):
- step (b) a weaker positive detection result at step (ii) relative to a stronger positive detection of step (iii) is indicative of a low analyte concentration;
- step (c) a weak positive detection result at both steps (ii) and (iii) is indicative of very high analyte concentration;
- step (ii) and step (iii) are equivalent, assessment of whether this result is strongly positive or weakly positive may be analysed relative to an objective standard or can be assessed by the person skilled in the art in a subjective manner based on the technical knowledge and experience which such a person would possess.
- the detection results are analysed by instrumentation it may be possible to precisely quantitate the concentration of analyte present in the sample.
- the detection results are analysed by less precise means (such as by the human eye) although a precise quantitative value is not obtained, in addition to overcoming the misleading results which are caused by the prozone phenomenon, the results obtained will nevertheless broadly indicate whether the analyte is present in low, high or very high levels. This level of information can be, nevertheless, of great value. For example, where a patient presents with symptoms of bowel cancer, obtaining a broad indication of whether the patient is bleeding mildly or severely is of assistance in planning further testing and/or treatment.
- the present invention provides a method of detecting the presence of an analyte in a biological sample, said method comprising the steps of:
- test matrix comprises multiple regions
- step (ii) wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).
- the present invention provides a method of detecting the presence of blood in a biological sample, said method comprising the steps of:
- test matrix comprises multiple regions
- step (ii) wherein the detection result obtained in step (ii) is analysed relative to the detection result obtained in step (iii).
- test directed to detecting unbound conjugate can be incorporated as an additional component of any new or existing test matrix format.
- the test format described in accordance with this aspect of the present invention may optionally comprise a fourth test matrix region which is impregnated with a chromogen such as guiac for the purpose of additionally and simultaneously detecting haem. This is of particular relevance where it is necessary to differentiate upper from lower gastrointestinal tract bleeding as hereinbefore described.
- Immunochromatographic tests typically use dried immunological reagents on a test strip. Liquid sample applied to the origin of the test strip flows through the various regions so that with a positive result, a coloured line develops in the upper region of the test strip. The reagents and sample then flow into an absorbent matrix at the top of the test strip. This absorbent is most commonly an absorbent paper, such as blotting paper.
- a strip of guaiac impregnated paper may be inserted at the upper region of the test strip, between the immunological detection zone and the absorbent.
- Figure 1 depicts a test matrix suitable for use according to the method of the present invention.
- the origin and the first section of the second region, which is impregnated with labelled antibody are made of the same material, which material is a conductive paper (Ahlstrom 1281).
- the capture antibody which is immobilised in the second section of the second region which region is made of Millipore nitrocellulose.
- a functional control line is also included in this region.
- the chromogen may be impregnated directly in the third region (the absorbent sink) or impregnated in a paper bridge between the second and third regions.
- Blood was diluted 1: 100, 1: 1000 and 1: 10,000 in immunological test buffer. This buffer caused lysis of the red blood cells, so that the haemoglobin was liberated into solution.
- the diluted blood samples were added to wells of a microtitre plate. Three negative control wells were included, each containing buffer alone.
- Immunological test strips (Enterix OBT) were modified so that the absorbent paper at the top of the strip was overlaid, in liquid conductive contact, with guaiac paper taken from a guaiac test (Hemoccult Sensa, SmithKline Diagnostics Inc., USA).
- the modified test strips were added to the microwells and yielded the following results:
- the purpose of the third line was to enable distinction between low signal strength due to prozone (high Hb concentration) from that due to low Hb concentration.
- the third line was dried to immobilise the Hb on the test strip.
- Line 2 control Ab (anti-goat Ab)
- Line 3 analyte (Hb)
- Line/zone 4 Guaiac (or similar) for detection of haem.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99957736A EP1131637A1 (en) | 1998-11-17 | 1999-11-17 | A method of detecting the presence of an analyte in a biological sample |
BR9915384-0A BR9915384A (en) | 1998-11-17 | 1999-11-17 | Methods for detecting the presence of blood in a biological sample, for detecting lower gastrointestinal bleeding, for detecting bleeding in the upper gastrointestinal tract, for diagnosing disease conditions, and for detecting the presence of an analyte in a biological sample |
IL14309899A IL143098A0 (en) | 1998-11-17 | 1999-11-17 | A method of detecting the presence of an analyte in a biological sample |
AU15358/00A AU1535800A (en) | 1998-11-17 | 1999-11-17 | A method of detecting the presence of an analyte in a biological sample |
JP2000582804A JP2002530651A (en) | 1998-11-17 | 1999-11-17 | Method for detecting the presence of an analyte in a biological sample |
MXPA01004918A MXPA01004918A (en) | 1998-11-17 | 1999-11-17 | A method of detecting the presence of an analyte in a biological sample. |
CA002350131A CA2350131A1 (en) | 1998-11-17 | 1999-11-17 | A method of detecting the presence of an analyte in a biological sample |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPP7134 | 1998-11-17 | ||
AUPP7134A AUPP713498A0 (en) | 1998-11-17 | 1998-11-17 | A method of detecting blood |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000029852A1 true WO2000029852A1 (en) | 2000-05-25 |
Family
ID=3811344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1999/001014 WO2000029852A1 (en) | 1998-11-17 | 1999-11-17 | A method of detecting the presence of an analyte in a biological sample |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1131637A1 (en) |
JP (1) | JP2002530651A (en) |
CN (1) | CN1334924A (en) |
AU (1) | AUPP713498A0 (en) |
BR (1) | BR9915384A (en) |
CA (1) | CA2350131A1 (en) |
IL (1) | IL143098A0 (en) |
MX (1) | MXPA01004918A (en) |
WO (1) | WO2000029852A1 (en) |
ZA (1) | ZA200103978B (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004109285A1 (en) * | 2003-06-03 | 2004-12-16 | Bayer Healthcare Llc | Native analyte as reference in lateral flow assays |
WO2005106498A1 (en) * | 2004-04-30 | 2005-11-10 | Enterix Pty. Limited | Device and method for detecting the presence of hemoglobin in a biological sample |
WO2006062800A1 (en) * | 2004-12-04 | 2006-06-15 | Freedom Health, Llc | Monoclonal and polyclonal antibodies to equine hemoglobin and apparatus and methods using the antibodies and/or peroxidase reactions in the identification and localization of ulcers in equines |
EP1927859A1 (en) | 2006-11-28 | 2008-06-04 | Freedom Health, LLC | Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines |
US7700271B2 (en) | 2001-09-12 | 2010-04-20 | The Walter And Eliza Hall Institute Of Medical Research | Method of diagnosis and treatment and agents useful for same |
US8101429B2 (en) | 2003-06-03 | 2012-01-24 | Siemens Healthcare Diagnostics Inc. | Native analyte as a reference in lateral flow assays |
US8349573B2 (en) | 2007-10-30 | 2013-01-08 | John Wan | Methods and device for the detection of occult blood |
RU2477754C2 (en) * | 2008-10-17 | 2013-03-20 | Актерм Инк. | Indicator strip for liquid and method |
US9903865B2 (en) | 2010-03-31 | 2018-02-27 | Sekisui Medical Co., Ltd. | Assay, immunochromatographic test strip, and assay reagent kit for measuring an analyte, using a hematocrit correction |
EP3188841A4 (en) * | 2014-09-02 | 2018-08-22 | Clinical Genomics Pty. Ltd. | Test device and method |
US10226238B2 (en) | 2011-09-12 | 2019-03-12 | Creatics Llc | Non-invasive methods of detecting target molecules |
US11391744B2 (en) | 2015-06-08 | 2022-07-19 | Arquer Diagnostic Limited | Methods and kits |
US11519916B2 (en) | 2015-06-08 | 2022-12-06 | Arquer Diagnostics Limited | Methods for analysing a urine sample |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4241822B2 (en) * | 2003-05-26 | 2009-03-18 | エフ.ホフマン−ラ ロシュ アーゲー | Use of protein MASP as a marker for colorectal cancer |
US7935538B2 (en) * | 2006-12-15 | 2011-05-03 | Kimberly-Clark Worldwide, Inc. | Indicator immobilization on assay devices |
ATE521894T1 (en) * | 2007-11-20 | 2011-09-15 | Hoffmann La Roche | METHOD FOR ASSESSING COLORECTAL CANCER USING A Stool Sample USING A MARKER COMBINATION OF CALPROTECTIN AND A HEMOGLOBIN/HAPTOGLOBIN COMPLEX |
WO2010040250A1 (en) | 2008-10-09 | 2010-04-15 | 红电医学科技股份有限公司 | A method for testing a liquid |
US7964370B2 (en) | 2008-10-17 | 2011-06-21 | Actherm Inc | Analytical strip and detecting method using the same |
JP2012521543A (en) | 2009-03-23 | 2012-09-13 | 紅電醫學科技股▲分▼有限公司 | Analytical strip and method for producing the same |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8418882A (en) * | 1981-07-16 | 1983-01-20 | F. Hoffmann-La Roche Ag | Detection of occult human blood |
WO1991012528A1 (en) * | 1990-02-07 | 1991-08-22 | Hygeia Sciences, Inc. | Device and method for conducting immunoassays |
EP0465266A1 (en) * | 1990-07-06 | 1992-01-08 | Sangstat Medical Corporation | Complementary visual signal immunoassay |
EP0724157A2 (en) * | 1995-01-30 | 1996-07-31 | Bayer Corporation | Quantitative detection of analytes on immunochromatographic strips |
WO1997035205A1 (en) * | 1996-03-20 | 1997-09-25 | Serex, Inc. | Chromatographic immunoassay device and method utilizing particle valency for quantitation |
AU2372597A (en) * | 1996-05-31 | 1997-12-04 | Bayer Corporation | Quantitative detection of analytes on immunochromatographic strips |
WO1998033069A1 (en) * | 1997-01-29 | 1998-07-30 | Smithkline Diagnostics, Inc. | Opposable-element assay device employing unidirectional flow |
AU7744098A (en) * | 1997-07-25 | 1999-02-04 | Bayer Corporation | Device and method for obtaining clinically significant analyte ratios |
-
1998
- 1998-11-17 AU AUPP7134A patent/AUPP713498A0/en not_active Abandoned
-
1999
- 1999-11-17 EP EP99957736A patent/EP1131637A1/en not_active Withdrawn
- 1999-11-17 JP JP2000582804A patent/JP2002530651A/en active Pending
- 1999-11-17 IL IL14309899A patent/IL143098A0/en unknown
- 1999-11-17 MX MXPA01004918A patent/MXPA01004918A/en unknown
- 1999-11-17 BR BR9915384-0A patent/BR9915384A/en not_active Application Discontinuation
- 1999-11-17 CN CN99814642A patent/CN1334924A/en active Pending
- 1999-11-17 WO PCT/AU1999/001014 patent/WO2000029852A1/en not_active Application Discontinuation
- 1999-11-17 CA CA002350131A patent/CA2350131A1/en not_active Abandoned
-
2001
- 2001-05-16 ZA ZA200103978A patent/ZA200103978B/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8418882A (en) * | 1981-07-16 | 1983-01-20 | F. Hoffmann-La Roche Ag | Detection of occult human blood |
WO1991012528A1 (en) * | 1990-02-07 | 1991-08-22 | Hygeia Sciences, Inc. | Device and method for conducting immunoassays |
EP0465266A1 (en) * | 1990-07-06 | 1992-01-08 | Sangstat Medical Corporation | Complementary visual signal immunoassay |
EP0724157A2 (en) * | 1995-01-30 | 1996-07-31 | Bayer Corporation | Quantitative detection of analytes on immunochromatographic strips |
WO1997035205A1 (en) * | 1996-03-20 | 1997-09-25 | Serex, Inc. | Chromatographic immunoassay device and method utilizing particle valency for quantitation |
AU2372597A (en) * | 1996-05-31 | 1997-12-04 | Bayer Corporation | Quantitative detection of analytes on immunochromatographic strips |
WO1998033069A1 (en) * | 1997-01-29 | 1998-07-30 | Smithkline Diagnostics, Inc. | Opposable-element assay device employing unidirectional flow |
AU7744098A (en) * | 1997-07-25 | 1999-02-04 | Bayer Corporation | Device and method for obtaining clinically significant analyte ratios |
Non-Patent Citations (5)
Title |
---|
ALLISON J.E. ET AL.: "A comparison of fecal occult-blood tests for colorectal-cancer screening", N. ENGL. J. MED.,, vol. 334, no. 3, 1996, pages 155 - 159 * |
DATABASE WPI Derwent World Patents Index; Class B04, AN 1992-134663/17 * |
PYE G. ET AL.: "An evaluation of Fecatwin/Feca EIA; a faecal occult blood test for detecting colonic neoplasia", EUROPEAN JOURNAL OF SURGICAL ONCOLOGY,, vol. 15, no. 5, 1989, pages 446 - 448 * |
ROCKEY D.C., AUSLANDER A., GREENBERG P.D.: "Detection of upper gastrointestinal blood with fecal occult blood tests", AM. J. GASTROENTEROL.,, vol. 94, no. 2, 1999, pages 344 - 350 * |
VAANANEN P. AND TENHUNEN R.: "Rapid immunochemical detection of fecal occult blood by use of a latex-agglutination test", CLINICAL CHEMISTRY,, vol. 34, no. 9, 1988, pages 1763 - 1776 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700271B2 (en) | 2001-09-12 | 2010-04-20 | The Walter And Eliza Hall Institute Of Medical Research | Method of diagnosis and treatment and agents useful for same |
WO2004109285A1 (en) * | 2003-06-03 | 2004-12-16 | Bayer Healthcare Llc | Native analyte as reference in lateral flow assays |
US8101429B2 (en) | 2003-06-03 | 2012-01-24 | Siemens Healthcare Diagnostics Inc. | Native analyte as a reference in lateral flow assays |
US7772012B2 (en) | 2004-04-30 | 2010-08-10 | Quest Diagnostics Investments Incorporated | Device for detecting the presence of hemoglobin in a biological sample |
WO2005106498A1 (en) * | 2004-04-30 | 2005-11-10 | Enterix Pty. Limited | Device and method for detecting the presence of hemoglobin in a biological sample |
US8497136B2 (en) | 2004-04-30 | 2013-07-30 | Quest Diagnostics Investments Incorporated | Device and method for detecting the presence of hemoglobin in a biological sample |
US8198036B2 (en) | 2004-04-30 | 2012-06-12 | Quest Diagnostics Investments Incorporated | Method for detecting the presence of hemoglobin in a biological sample |
AU2005238549B2 (en) * | 2004-04-30 | 2009-12-24 | Enterix Pty. Limited | Device and method for detecting the presence of hemoglobin in a biological sample |
US8168446B2 (en) | 2004-12-04 | 2012-05-01 | Freedom Health, Llc | Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines |
US7629180B2 (en) | 2004-12-04 | 2009-12-08 | Freedom Health, Llc | Test kit for the rapid detection and localization of digestive tract bleeding in equines |
WO2006062800A1 (en) * | 2004-12-04 | 2006-06-15 | Freedom Health, Llc | Monoclonal and polyclonal antibodies to equine hemoglobin and apparatus and methods using the antibodies and/or peroxidase reactions in the identification and localization of ulcers in equines |
AU2007216684A8 (en) * | 2006-11-26 | 2013-07-25 | Freedom Health, Llc | Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines |
AU2007216684B2 (en) * | 2006-11-26 | 2013-07-11 | Freedom Health, Llc | Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines |
AU2007216684B8 (en) * | 2006-11-26 | 2013-07-25 | Freedom Health, Llc | Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines |
CN101221174A (en) * | 2006-11-28 | 2008-07-16 | 自由健康有限公司 | Apparatus and methods for identification and localization of ulcers and other digestive tract bleeding in equines |
EP1927859A1 (en) | 2006-11-28 | 2008-06-04 | Freedom Health, LLC | Monoclonal and polyclonal antibodies to equine albumin and hemoglobin and apparatus and methods using the antibodies in the identification and localization of ulcers and other digestive tract bleeding in equines |
US8349573B2 (en) | 2007-10-30 | 2013-01-08 | John Wan | Methods and device for the detection of occult blood |
RU2477754C2 (en) * | 2008-10-17 | 2013-03-20 | Актерм Инк. | Indicator strip for liquid and method |
US9903865B2 (en) | 2010-03-31 | 2018-02-27 | Sekisui Medical Co., Ltd. | Assay, immunochromatographic test strip, and assay reagent kit for measuring an analyte, using a hematocrit correction |
US10226238B2 (en) | 2011-09-12 | 2019-03-12 | Creatics Llc | Non-invasive methods of detecting target molecules |
EP3188841A4 (en) * | 2014-09-02 | 2018-08-22 | Clinical Genomics Pty. Ltd. | Test device and method |
US11391744B2 (en) | 2015-06-08 | 2022-07-19 | Arquer Diagnostic Limited | Methods and kits |
US11519916B2 (en) | 2015-06-08 | 2022-12-06 | Arquer Diagnostics Limited | Methods for analysing a urine sample |
Also Published As
Publication number | Publication date |
---|---|
AUPP713498A0 (en) | 1998-12-10 |
ZA200103978B (en) | 2002-05-15 |
MXPA01004918A (en) | 2002-04-24 |
IL143098A0 (en) | 2002-04-21 |
JP2002530651A (en) | 2002-09-17 |
BR9915384A (en) | 2001-07-31 |
EP1131637A1 (en) | 2001-09-12 |
CN1334924A (en) | 2002-02-06 |
CA2350131A1 (en) | 2000-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000029852A1 (en) | A method of detecting the presence of an analyte in a biological sample | |
FI78320B (en) | FOERFARANDE FOER PAOVISNING AV DOLT HUMANBLOD I ETT AVFOERINGSPROV. | |
US8497136B2 (en) | Device and method for detecting the presence of hemoglobin in a biological sample | |
JP4197180B2 (en) | Method for measuring endocrine substances in specimens | |
JPS6091263A (en) | Immunological determination method of protein in body fluid | |
US20080227208A1 (en) | Devices and Methods for Detection of Occult Blood | |
JP2004530110A (en) | Ovarian storage urine assay | |
KR100394940B1 (en) | Method for measuring serum asialo-glycoprotein concentration for diagnosis of hepatic disease and a kit therefor | |
CN113156105A (en) | A type botulinum toxin rapid quantitative detection card | |
US6686167B2 (en) | Test device for detecting semen and method of use | |
EP2110668A1 (en) | Detection test assembly for detecting the presence of a substance in a sample | |
KR20160120675A (en) | Rapid Quantitative Diagnostic Kit | |
US20030027222A1 (en) | Test device for detecting human blood and method of use | |
Crouch et al. | A Comparison of ONTRAK TESTCUP™, Abuscreen ONTRAK®, Abuscreen ONLINE®, and GC/MS Urinalysis Test Results | |
KR100834932B1 (en) | Kit for diagnosis of hepatic disease using ratio serum asialo-?1-acid glycoprotein concentration and ?1-acid glycoprotein concentration | |
Patzl et al. | Determination of autoantibodies to thyroglobulin, thyroxine and triiodothyronine in canine serum | |
AU1535800A (en) | A method of detecting the presence of an analyte in a biological sample | |
CN102971630A (en) | Marker for detection and/or discrimination of non-alcoholic steatohepatitis, method for detection and/or discrimination of non-alcoholic steatohepatitis, and kit for use in the method | |
JP2002528722A (en) | Assays for autoantibodies | |
Kim et al. | A qualitative agar gel immunoprecipitin (IP) test for detection of fecal occult human hemoglobin | |
JP2004251851A (en) | Examination method of feces component | |
JPH10115616A (en) | Apparatus or inspection human blood | |
CN118112260A (en) | Method for semi-quantitatively detecting concentration of hemoglobin in feces | |
CN116047079A (en) | Application of homocysteine modified serum protein in prostate cancer prediction, diagnosis and screening | |
Waritani et al. | One-step immunochromatography assay for detection of high-level canine serum trypsin-like immunoreactivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99814642.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2000 15358 Country of ref document: AU Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 15358/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2350131 Country of ref document: CA Ref document number: 2350131 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 143098 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999957736 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/03978 Country of ref document: ZA Ref document number: PA/a/2001/004918 Country of ref document: MX Ref document number: 200103978 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2000 582804 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1999957736 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09856105 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999957736 Country of ref document: EP |